

---

---

# SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

---

## FORM 8-K

---

**CURRENT REPORT**  
**Pursuant to Section 13 or 15(d) of**  
**the Securities Exchange Act of 1934**

**Date of report (Date of earliest event reported): June 18, 2019**

---

# SCPHARMACEUTICALS INC.

(Exact Name of Registrant as Specified in its Charter)

---

**Delaware**  
(State or other jurisdiction  
of incorporation or organization)

**001-38293**  
(Commission  
File Number)

**46-5184075**  
(I.R.S. Employer  
Identification No.)

**2400 District Avenue, Suite 310**  
**Burlington, Massachusetts**  
(Address of principal executive offices)

**01803**  
(Zip Code)

**Registrant's telephone number, including area code: (617) 517-0730**

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

<u>Title of each class</u>	<u>Trading Symbol(s)</u>	<u>Name of each exchange on which registered</u>
<b>Common stock, par value \$0.0001</b>	<b>SCPH</b>	<b>The Nasdaq Global Select Market</b>

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

---

---

**Item 5.07 Submission of Matters to a Vote of Security Holders.**

The 2019 Annual Meeting of Stockholders (the “Annual Meeting”) of scPharmaceuticals Inc. (the “Company”) was held on June 18, 2019. Proxies were solicited pursuant to the Company’s proxy statement filed on April 30, 2019, with the Securities and Exchange Commission under Section 14(a) of the Securities Exchange Act of 1934, as amended.

The number of shares of the Company’s common stock, \$0.0001 par value per share (“Common Stock”), entitled to vote at the Annual Meeting was 18,580,430. The number of shares of Common Stock present or represented by valid proxy at the Annual Meeting was 15,657,729, representing 84.27% of the total number of shares of Common Stock entitled to vote at the Annual Meeting. Each share of Common Stock was entitled to one vote with respect to matters submitted to the Company’s stockholders at the Annual Meeting.

At the Annual Meeting, the Company’s stockholders were asked (i) to elect three Class II directors to the Company’s Board of Directors, each to hold office until the 2022 annual meeting of stockholders and until his or her successor is duly elected and qualified, or until his or her earlier resignation or removal and (ii) to ratify the appointment of RSM US LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2019.

The voting results reported below are final.

**Proposal 1 – Election of Directors**

Mette Kirstine Agger, Mason Freeman M.D., and Minnie Baylor-Henry were duly elected to the Company’s Board of Directors as Class II directors. The results of the election were as follows:

NOMINEE	FOR		%	% WITHHELD		BROKER NON- VOTES
Mette Kirstine Agger	13,313,661	98.83	%	157,514	1.17	% 2,186,554
Mason Freeman, M.D.	13,333,610	98.98	%	137,565	1.02	% 2,186,554
Minnie Baylor-Henry	13,406,074	99.52	%	65,101	0.48	% 2,186,554

Proposal 2 – Ratify the Appointment of Independent Registered Public Accounting Firm

The appointment of RSM US LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2019 was ratified. The results of the ratification were as follows:

	<u>FOR</u>		<u>AGAINST</u>		<u>ABSTAIN</u>	
<b>NUMBER</b>	15,616,814		40,802		113	
<b>PERCENTAGE OF VOTED</b>	99.73	%	0.26	%	0.00	%

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: June 20, 2019

**SCPHARMACEUTICALS INC.**

By: /s/ John H. Tucker

Name: John H. Tucker

Title: President, Chief Executive Officer, Principal  
Executive Officer and Principal Financial Officer